Lia Palomba
@LiaPalomba
oncologist @sloankettering lymphoma expert immunotherapy CAR T cells Waldenstrom’s macroglobulinemia
Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone #lymphoma, as well as a durable safety. @LiaPalomba @sloankettering @bmsnews hubs.li/Q03t2mVR0
Lymphoma Microenvironment Archetype Profiles (LymphoMAPs). Just presented by @dgermain21 at #18icml @icmlugano, now available online in Cancer Cell. #lmsm @washumedicine @MDAndersonNews. cell.com/cancer-cell/fu…
Grazie Franco and the whole Lugano/Bellinzona team for yet another great #ICML. See you in 2027!
CONGRESS | #18ICML | PRESENTATION M. Lia Palomba @LiaPalomba @MSKCancerCenter presents results from the 3L+ R/R MZL cohort of the phase II TRANSCEND FL trial (N = 67). In patients with R/R MZL, liso-cel demonstrated deep and durable responses (ORR, 95.5%; CR rate, 62.1%) with…
Dr. Palomba on liso-cel in 3L+ R/R MZL: - ORR 95%, CR 62% - 2y estimated PFS: 85.7% - CRS in 76% (4% grade ≥3) - Very promising for this challenging population @MSK_DeptOfMed #18ICML
Together we lead, we learn, we lift each other up. Thank you to all who joined our WiL gathering at #18ICML — an inspiring evening filled with connection, purpose, and power. Let’s keep building this global community, one voice at a time. 🌍 #womeninhematology #ICML2025
Featured today by @MSKLibrary: CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma dx.doi.org/10.1038/s41408… #CAR_TCellTherapy #LargeBCellLymphoma #ExtranodalDisease #LymphomaResearch #Immunotherapy #OncologyUpdates #CancerTreatment…
New research presented by MSK gastrointestinal medical oncologist @YJanjigianMD at #AACR25 shows that a simple blood test can help doctors identify which patients are most likely to benefit from #immunotherapy after cancer surgery to remove tumors — potentially preventing the…
This past weekend, @MSKCancerCenter welcomed a global audience to the 9th Annual Symposium on #Lymphoma, held both in New York City and virtually. We extend our sincere appreciation to all the presenters for their valuable insights—including keynote speakers @ChrisRFlowersMD,…
Please check out our paper published in @NatureMedicine on our Phase I trial of AFM13-precomplexed cord blood NK cells in relapsed/refractory CD30+ lymphomas. Led by Dr. Yago Nieto and an outstanding team of coauthors and collaborators, this study marks the first clinical…
Findings from a Phase I trial suggest natural killer cells pre-complexed with AFM13 has promise for specific patients with lymphoma and may be adapted for more cancer types in the future. Learn more: brnw.ch/21wRN45 #EndCancer
Nice data, congrats to the authors Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…
The science of pasta cacio e pepe 🇮🇹👨🍳 "Finally, we present a scientifically optimized recipe based on our findings, enabling a consistently flawless execution of this classic dish." Applied science at its best, with real-world impact arxiv.org/abs/2501.00536
A phase 1 study led by @jaeparkmd evaluated a novel CAR T cell therapy for people with large B-cell #lymphoma. Of 28 trial participants, the overall response rate was 82% and complete response was 71%. Patients did well on low doses that minimized side effects. #lymsm…
New research from @MSKCancerCenter takes a step toward off-the-shelf CAR T cell therapy for #cancer. Author Karlo Perica explains his and Michel Sadelain's recent study in @Nature that demonstrated cells from healthy donors can be stored for future use. bit.ly/40W306e
L.A. Oncologist's Family Is Evacuated, Follows Him to Hospital to Help people.com/doctor-family-…
Happy to share our work just published online in haematologica.org/article/view/1… @Haematologica . We dissected the composition and spatial interactions of the TME in GCB, ABC and testicular DLBCLs and found biologically and clinically relevant differences between the subtypes.
At the Sunday evening #ASH24 poster session, an important abstract will be presented demonstrating that liso-cel CAR T-cell therapy can cure patients with relapsed DLBCL, with 52% of patients without disease progression at 5 years after CAR-T. #lymsm #tcellrx
Can we develop a new visual language to describe early CAR-T toxicity? 👉 In CAR-TOGRAPHY we graded >32,500 pt days across 4 sites in 902 CAR-T recipients, yielding >125,000 unique toxicity datapoints. 👉 Develop new metrics to describe early toxicity: CTI & tox phenotypes
CARs vs bispecifics: the race is on! | Blood | American Society of Hematology ashpublications.org/blood/article/…